Tyra Biosciences Reports Third Quarter 2022 Financial Results and Highlights

-Pipeline on track; SURF301 study to be initiated; IND for TYRA-200 to be filed by year-end 2022- -Well-capitalized with cash and cash equivalents of $263.2 million as of Q3 2022- CARLSBAD, Calif., Nov. 3, 2022 /PRNewswire/ — Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology…

Click here to view original post